Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Daratumumab increases PFS in patients with transplant-ineligible multiple myeloma

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 06.12.18
Views: 528

Prof Thierry Facon - Hôpital Claude Huriez, Lille, France

Dr Thierry Facon gives a press conference at ASH 2018 about the use of daratumumab in transplant-ineligible multiple myeloma patients.

Watch his interview with ecancer here.

Read more about this work here

Related videos

follow us

WIN 2019

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation